QIAGEN N.V. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
QIAGEN N.V. (QGEN) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $0 for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-03-20
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.00 20-F · filed 2026-03-20 | |
| 2024-12-31 | $250.00K 20-F · filed 2026-03-20 | |
| 2023-12-31 | $4.16M 20-F · filed 2025-03-31 | |
| 2022-12-31 | $0.00 20-F · filed 2024-03-11 | |
| 2018-12-31 | $0.00 20-F · filed 2019-03-06 | |
| 2017-12-31 | $5.10M 20-F · filed 2020-03-02 | $5.14M 20-F · filed 2019-03-06 |